1. Home
  2. CBNK vs DCTH Comparison

CBNK vs DCTH Comparison

Compare CBNK & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CBNK

Capital Bancorp Inc.

N/A

Current Price

$42.10

Market Cap

560.3M

Sector

Finance

ML Signal

N/A

DCTH

Delcath Systems Inc.

N/A

Current Price

$21.56

Market Cap

578.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CBNK
DCTH
Founded
1974
1988
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
560.3M
578.4M
IPO Year
2018
2015

Fundamental Metrics

Financial Performance
Metric
CBNK
DCTH
Price
$42.10
$21.56
Analyst Decision
Hold
Strong Buy
Analyst Count
5
5
Target Price
★ $44.08
$26.60
AVG Volume (30 Days)
136.9K
★ 424.9K
Earning Date
10-26-2026
11-09-2026
Dividend Yield
★ 1.31%
N/A
EPS Growth
60.85
★ 107.53
EPS
★ 2.40
0.21
Revenue
N/A
N/A
Revenue This Year
$8.98
$36.96
Revenue Next Year
$10.68
$18.85
P/E Ratio
★ $17.82
$499.25
Revenue Growth
N/A
N/A
52 Week Low
$26.40
$8.12
52 Week High
$44.76
$20.03

Technical Indicators

Market Signals
Indicator
CBNK
DCTH
Relative Strength Index (RSI) 58.96 82.16
Support Level $35.70 $10.76
Resistance Level N/A N/A
Average True Range (ATR) 0.94 0.84
MACD -0.05 0.72
Stochastic Oscillator 40.77 97.79

Price Performance

Historical Comparison
CBNK
DCTH

About CBNK Capital Bancorp Inc.

Capital Bancorp Inc is a bank holding company. The company through its holdings operates as a commercial-focused community bank that serves businesses, not-for-profit associations, and entrepreneurs throughout the region. The bank operates through four divisions including Commercial Banking, Capital Bank Home Loans, OpenSky, and Windsor Advantage. The company generates majority revenue from the Commercial bank sector. Commercial Banking division focuses on providing personalized service to commercial clients throughout the operations supplemented by lending outside primary market as well as engaging in government guaranteed lending on a national basis.

About DCTH Delcath Systems Inc.

Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.

Share on Social Networks: